Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kumudha Balakrishnan

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Leukemia & Lymphoma|May 10, 2013
Uncoupling endoplasmic reticulum stress and autophagy: a potential implication for chronic lymphocytic leukemia therapyKumudha Balakrishnan, Varsha Gandhi
Investigational New Drugs|August 3, 2013
Bcl-2 antagonists: a proof of concept for CLL therapyKumudha Balakrishnan, Varsha Gandhi
Leukemia & Lymphoma|July 12, 2011
The micros in harmony: microRNA and microenvironmentKumudha Balakrishnan, Varsha Gandhi
Seminars in Oncology|December 19, 2007
Pharmacology and mechanism of action of forodesine, a T-cell targeted agentVarsha Gandhi, Kumudha Balakrishnan
Leukemia & Lymphoma|May 9, 2012
CCL2 in chronic lymphocytic leukemia: a macro in microenvironment?Varsha Gandhi, Kumudha Balakrishnan
Expert Opinion on Investigational Drugs|March 14, 2012
Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemiaKumudha Balakrishnan, Varsha Gandhi
Biochemical Pharmacology|August 11, 2010
Inflammation and survival pathways: chronic lymphocytic leukemia as a model systemLisa S Chen, Kumudha Balakrishnan, Varsha Gandhi
British Journal of Haematology|August 28, 2009
Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesisJennifer B Dennison, Kumudha Balakrishnan, Varsha Gandhi
Blood|October 25, 2008
Mcl-1: the 1 in CLLVarsha Gandhi, Kumudha Balakrishnan, Lisa S Chen
Leukemia & Lymphoma|August 8, 2012
Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cellsKumudha Balakrishnan, Sumesh Aggarwal, William Wierda, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Leukemia & Lymphoma|May 10, 2013
Uncoupling endoplasmic reticulum stress and autophagy: a potential implication for chronic lymphocytic leukemia therapyKumudha Balakrishnan, Varsha Gandhi
Investigational New Drugs|August 3, 2013
Bcl-2 antagonists: a proof of concept for CLL therapyKumudha Balakrishnan, Varsha Gandhi
Leukemia & Lymphoma|July 12, 2011
The micros in harmony: microRNA and microenvironmentKumudha Balakrishnan, Varsha Gandhi
Seminars in Oncology|December 19, 2007
Pharmacology and mechanism of action of forodesine, a T-cell targeted agentVarsha Gandhi, Kumudha Balakrishnan
Leukemia & Lymphoma|May 9, 2012
CCL2 in chronic lymphocytic leukemia: a macro in microenvironment?Varsha Gandhi, Kumudha Balakrishnan
Expert Opinion on Investigational Drugs|March 14, 2012
Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemiaKumudha Balakrishnan, Varsha Gandhi
Biochemical Pharmacology|August 11, 2010
Inflammation and survival pathways: chronic lymphocytic leukemia as a model systemLisa S Chen, Kumudha Balakrishnan, Varsha Gandhi
British Journal of Haematology|August 28, 2009
Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesisJennifer B Dennison, Kumudha Balakrishnan, Varsha Gandhi
Blood|October 25, 2008
Mcl-1: the 1 in CLLVarsha Gandhi, Kumudha Balakrishnan, Lisa S Chen
Leukemia & Lymphoma|August 8, 2012
Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cellsKumudha Balakrishnan, Sumesh Aggarwal, William Wierda, et al.
Pageof 5